News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|November 8, 2024

Unmet Needs in Generalized Myasthenia Gravis

Author(s)Nicholas J. Silvestri, MD, FAAN, Ali Habib, MD, Neelam Goyal, MD

Key Takeaways

Current MG treatments often have limited efficacy and significant side effects, necessitating more effective and targeted therapies.
Early and accurate diagnosis is crucial, highlighting the need for better diagnostic tools in MG management.
Comprehensive patient education and support systems are essential to improve the quality of life for MG patients.
Research into MG's underlying pathophysiology is vital for developing novel therapeutic approaches to address unmet needs.

SHOW MORE

Panelists discuss how certain aspects of myasthenia gravis management remain challenging, identifying ongoing unmet needs in diagnosis, treatment, and patient care.

Episodes in this series

EP. 1 Generalized Myasthenia Gravis Presentation and Diagnosis

EP. 1 Generalized Myasthenia Gravis Presentation and Diagnosis

EP. 2 Generalized Myasthenia Gravis Classification and Treatment Strategy

EP. 2 Generalized Myasthenia Gravis Classification and Treatment Strategy

EP. 3 Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

EP. 3 Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

EP. 4 Outcome Measures in Generalized Myasthenia Gravis

EP. 4 Outcome Measures in Generalized Myasthenia Gravis

EP. 5 Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

EP. 5 Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

EP. 6 Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

EP. 6 Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

EP. 7 Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

EP. 7 Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

EP. 8 Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

EP. 8 Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

EP. 9 Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 9 Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 10 Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 10 Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 11 Use of Targeted Agents in Generalized Myasthenia Gravis

EP. 11 Use of Targeted Agents in Generalized Myasthenia Gravis

EP. 12 Management of Generalized Myasthenia Gravis in Pediatric Patients

EP. 12 Management of Generalized Myasthenia Gravis in Pediatric Patients

EP. 13 Unmet Needs in Generalized Myasthenia Gravis

EP. 13 Unmet Needs in Generalized Myasthenia Gravis

EP. 14 Generalized Myasthenia Gravis Pipeline

EP. 14 Generalized Myasthenia Gravis Pipeline

EP. 15 New Data from AANEM 2024 in Generalized Myasthenia Gravis

EP. 15 New Data from AANEM 2024 in Generalized Myasthenia Gravis

EP. 16 Clinical Pearls for Management of Generalized Myasthenia Gravis

EP. 16 Clinical Pearls for Management of Generalized Myasthenia Gravis

Video content above is prompted by the following:

What continue to be unmet needs in myasthenia gravis?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

The Evolving Landscape of Secondary Stroke Prevention

ByMike Sharma, MD

December 1st 2025

Lessons from the PACIFIC-STROKE Phase 2 Trial

ByMike Sharma, MD

November 24th 2025

Optimizing Treatment Selection and Moving Beyond the Plateau

ByAmit Sachdev, MD, MS

November 20th 2025

Overview and Design of the OCEANIC-STROKE Trial

ByMike Sharma, MD

November 17th 2025

Evolution of CIDP Clinical Trials and Patient Protection

ByAmit Sachdev, MD, MS

November 13th 2025

Latest CME

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Survey identifies Fever-Related Seizure Reduction as Key Feature of CDKL5 Deficiency Disorder

FDA Action Update, November 2025: Approvals, Clearance, and Boxed Warning

Cell Therapy Deramiocel Meets Primary End Point in Phase 3 DMD Cardiomyopathy Trial

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS

Long-Term Expanded Access Program Data Support Phase 3 Development of Bexicaserin in Developmental Epileptic Encephalopathies

© 2025 MJH Life Sciences^®

All rights reserved.